行情

RGLS

RGLS

Regulus
NASDAQ

实时行情|Nasdaq Last Sale

0.7800
+0.0001
+0.01%
已收盘, 16:00 12/09 EST
开盘
0.7800
昨收
0.7799
最高
0.7870
最低
0.7310
成交量
4.33万
成交额
--
52周最高
1.650
52周最低
0.5026
市值
1,632.31万
市盈率(TTM)
-0.4224
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

RGLS 新闻

  • 报告:6家硅谷巨头过去10年全球避税1000亿美元
  • 新浪科技.6天前
  • 报告:秘鲁2019年三季度倒闭公司数量同比增五成
  • 中国新闻网.6天前
  • 英国保守党支持率较工党的领先优势扩大至12个百分点
  • 新浪财经综合.6天前
  • 拼多多无证经营支付踩雷区 上海央行正督促其整改
  • 21世纪经济报道.6天前

更多

所属板块

生物技术和医学研究
+0.52%
制药与医学研究
+0.23%

热门股票

名称
价格
涨跌幅

RGLS 简况

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
展开

Webull提供Regulus Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。